• DarioHealth Corp DRIO.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -49 cents. The mean expectation of three analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -35 cents to -16 cents per share.

• Revenue rose 111% to $7.42 million from a year ago; analysts expected $7.40 million.

• DarioHealth Corp's reported EPS for the quarter was a loss of 25 cents​.

• The company reported a quarterly loss of $14.61 million.

• DarioHealth Corp shares had fallen by 13.8% this quarter and lost 43.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 32.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for DarioHealth Corp is $3.50

This summary was machine generated from LSEG data November 7 at 08:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)